Assess the Oral Bioavailability of New ABT-263 Formulations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2008
This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Epistemonikos ID: a5277238f32de1db30cbc97a37adc894354c07de
First added on: Jan 21, 2022